Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 5/20 | 0.54 |
| ▸ | RORC | P51449 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | BCHE | P06276 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27650715 | 0.85 | MEN1 (0.60) | ACHERORCMAPTKDM4EALDH1A1 | |
| SCHEMBL16619393 | 0.84 | CA1 (0.53) | ACHERORCMAPTKDM4EALDH1A1 | |
| SCHEMBL28102096 | 0.83 | MAPT (0.51) | ACHERORCMAPTKDM4EALDH1A1 | |
| SCHEMBL16619803 | 0.82 | CA1 (0.46) | MAPTALDH1A1HTTMEN1KMT2A | |
| SCHEMBL9490013 | 0.78 | RORC (0.51) | ACHERORCMAPTKDM4EALDH1A1 | |
| SCHEMBL4152933 | 0.78 | MAPT (0.59) | MAPTKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL19876877 | 0.77 | MAPT (0.49) | MAPTALDH1A1HTTMEN1KMT2A | |
| SCHEMBL27852681 | 0.77 | ALDH1A1 (0.72) | ACHERORCMAPTKDM4EALDH1A1 | |
| SCHEMBL17976214 | 0.76 | SMN1; SMN2 (0.61) | MAPTKDM4EKMT2A | |
| SCHEMBL13102342 | 0.75 | MAPT (0.70) | ACHERORCMAPTKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10227327-B2 | Inhibitors of metallo-beta-lactamase (MBL) comprising a zinc chelating moiety | Universitetet | Oslo (NO) | 2019-03-12 | — | — | US | disclosed |
| EP-3052135-B1 | INHIBITORS OF METALLO-BETA-LACTAMASE (MBL) COMPRISING A ZINC CHELATING MOIETY | UNIV OSLO (NO) | 2018-07-18 | — | — | EP | disclosed |
| CN-106029104-A | Inhibitors of metallo-beta-lactamase (MBL) comprising a zinc chelating moiety | 奥斯陆大学 | 2016-10-12 | — | — | CN | disclosed |
| US-20160244431-A1 | Inhibitors of Metallo-Beta-Lactamase (MBL) Comprising a Zinc Chelating Moiety | UNIVERSITETET I OSLO (NO) | 2016-08-25 | — | — | US | disclosed |
| EP-3052135-A1 | INHIBITORS OF METALLO-BETA-LACTAMASE (MBL) COMPRISING A ZINC CHELATING MOIETY | Universitetet I Oslo (NO) | 2016-08-10 | — | — | EP | disclosed |
| WO-2015049546-A1 | INHIBITORS OF METALLO-BETA-LACTAMASE (MBL) COMPRISING A ZINC CHELATING MOIETY | UNIVERSITETET I OSLO (NO) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160244431-A1 | Inhibitors of Metallo-Beta-Lactamase (MBL) Comprising a Zinc Chelating Moiety | SLC30A6, DDO, SLC30A7 | ACHE 758/4885RORC 4208/4885MAPT 3945/4885 |
| US-10227327-B2 | Inhibitors of metallo-beta-lactamase (MBL) comprising a zinc chelating moiety | SLC30A6, DDO, SLC30A7 | ACHE 758/4885RORC 4208/4885MAPT 3945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.